Project Grant R43DK138554
Award Date
9/1/23
Completion Date
6/30/24
Dollars Obligated
$335K
Awardee
Adepthera LLC (QDWUGUNKHMT5)
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
San Jose, CA 95138, USA
Similar Awards
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $687,416 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Lynntech Inc., a small business technology development company in College Station, Texas. The grant supports the development of a cutaneous gel that can controllably deliver a therapeutic with an intriguing mechanism of action to effectively address impaired wound healing in diabetic foot...
This federal Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports the development of a fibronectin matrix mimetic called "Chimectin" as a potential therapeutic for chronic wound healing. The $388,193 award to EDI Therapeutics LLC, granted on May 1, 2024, aims to fully characterize the tissue responses to Chimectin in diabetic...
The federal Project Grant award of $649,984 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) is supporting the development of Provasliex Gel, a zwitterionic hydrogel that delivers controlled release of platelet-derived growth factor (PDGF) to address the need for improved treatments for diabetic foot ulcers (DFUs). The goal is to demonstrate the feasibility of using...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $425,176 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to Eden Medical, Inc. to develop the "Smart Foot Mat" (SFM), a home-based device for monitoring diabetic foot complications. The SFM leverages near-infrared spectroscopy to provide quantitative metrics on ulcer risk, allowing high-risk diabetic patients to track their foot health and receive early...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $324,998 Project Grant (CFDA 93.847) to Minutia Inc., a minority-owned, woman-owned, and Black American-owned biotechnology research company, to advance the development of stem cell-derived pancreatic islet cell therapies for the treatment of type 1 diabetes. The key objectives of this 1-year project are to: 1) Assess the impact of genetic modifications to enhance the resilience of stem cell-derived islet...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research, supports the development of a deep learning-based platform for the remote management and analysis of diabetic foot ulcers (DFUs). The $312,492 award to Anxomics LLC, a woman-owned small business, aims to optimize and validate the platform's ability to accurately detect wound infection and ischemia status...
The federal Project Grant award R43DK137616 for $275,766.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds Biosurfaces Inc., a for-profit medical device company, to develop and evaluate an implantable, electrospun cell chamber device loaded with human pancreatic islets. The device aims to provide an immune-protected environment to support...
The University of North Texas Health Science Center at Fort Worth (UNTHSC) was awarded a $268,377 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant is focused on the development and validation of a novel device that utilizes high-frequency, low amplitude vibration to enhance the healing of stage 2 diabetic foot ulcers (DFUs). The key objectives are...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Fibrotherapeutics Inc. a $675,480 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop a novel therapeutic for chronic kidney disease. The project aims to determine the therapeutic index and further validate the efficacy of a modified, water-soluble, orally-active caveolin-1 scaffolding domain (CSD) peptide in mouse models of kidney fibrosis. Key...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is funding the development of innovative artificial intelligence (AI)-based methods to support the discovery of potent, orally available small-molecule heparanase inhibitors. Heparanase is an enzyme that plays a key role in the development of diabetic nephropathy, a serious complication of...